Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEVAMAINT: Fluoropyrimidine + Bevacizumab vs Fluoropyrimidine Maintenance in Metastatic Colorectal Cancer
NCT04188145Phase 3Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jan 2020
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in colorectal cancer (CRC), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Jan 2020; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04188145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188145.